DA Willard - Concepedia

Author

DA Willard

Institute for Medical Research

Also Known As

D A Willard, D Willard, D. A. WILLARD, D. A. Willard, D. WILLARD, D. Willard, DA Willard

Publications

732

Citations

H-Index

Concepts

All Affiliations

Institute for Medical Research University Medical Center of Princeton Princeton University Bristol-Myers Squibb (Germany)Bristol-Myers Squibb (United States)

About

DA Willard is an author at Institute for Medical Research specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	281
2	Health Sciences	1	1	36
3	Applied Physiology	1	1	36
4	Diabetes	1	1	78
5	Endocrinology	1	1	64

DA Willard

Publications

699

Citations

H-Index

Page 1

	Year	Citations
Disposition of pravastatin sodium, a tissue‐selective HMG‐CoA reductase inhibitor, in healthy subjects. S. M. Singhvi, HY Pan, R. A. Morrison, British Journal of Clinical Pharmacology	1990	179
Disposition of fosinopril sodium in healthy subjects. S. M. Singhvi, KL Duchin, R. A. Morrison, British Journal of Clinical Pharmacology	1988	91
Metabolic Studies in Patients with Nadolol: Oral and Intravenous Administration Jacques Dreyfuss, L. J. Brannick, R. A. Vukovich, The Journal of Clinical Pharmacology Metabolic SyndromeHypertensionMetabolic StudiesMetabolic DisorderPharmacological Study	1977	78
Aminoglutethimide in the Treatment of Cushing's Syndrome Robert I. Misbin, John J. Canary, DA Willard The Journal of Clinical Pharmacology Adrenal GlandPharmacologyPituitary OriginBilateral HyperplasiaPharmacotherapy	1976	64
Pharmacokinetics of Nadolol, a Beta‐Receptor Antagonist: Administration of Therapeutic Single‐ and Multiple‐Dosage Regimens to Hypertensive Patients Jacques Dreyfuss, D. L. Griffith, S. M. Singhvi, The Journal of Clinical Pharmacology HypertensionPharmacokinetic ModelingCardiovascular DiseaseHypertensive PatientsMedicine	1979	50
Pharmacokinetic interaction between propranolol and the HMG‐CoA reductase inhibitors pravastatin and lovastatin. HY Pan, Joseph Triscari, SA Smith, British Journal of Clinical Pharmacology	1991	43
Endocrine and Cardiovascular Consequences of Angiotensin Converting Enzyme Inhibition Robert A. Vukovich, DA Willard, L. J. Brannick Journal of International Medical Research	1977	41
Effect of beta‐blockers on exercise double product (systolic blood pressure x heart rate). R. A. Vukovich, JE Foley, B. Greg Brown, British Journal of Clinical Pharmacology HypertensionPhysical ActivityCardiovascular PharmacologyPharmacotherapyExercise Double Product	1979	36
Pharmacokinetics of teicoplanin in children Eliane Tarral, F. Jehl, Antoine Tarral, Journal of Antimicrobial Chemotherapy Therapeutic Drug MonitoringSerum SamplingMedicinePediatricsSingle Dose	1988	32
Dose proportionality of nadolol pharmacokinetics after intravenous administration to healthy subjects R. A. Morrison, S. M. Singhvi, William A. Creasey, European Journal of Clinical Pharmacology Nadolol PharmacokineticsDose ProportionalityHealthy SubjectsPharmacodynamicsPharmacological Study	1988	21

Page 1